Propafenone‐ <i>vs</i> . amiodarone‐associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure
Propafenone was not significantly associated with increased risk of proarrhythmia and mortality when compared to amiodarone in atrial fibrillation patients with heart failure in contemporary real-world settings. Prospective studies are needed to determine whether propafenone should definitely be avoided in these patients.
Authors
- Bi‐Li Chen (ORCID: https://orcid.org/0000-0003-0242-1389)
- Chun‐Yao Huang (ORCID: https://orcid.org/0000-0002-8978-7879)
- Gregory Y.H. Lip (ORCID: https://orcid.org/0000-0002-7566-1626)
- Lingyun Cheng (ORCID: https://orcid.org/0000-0002-8156-5550)
- Chien‐Yi Hsu (ORCID: https://orcid.org/0000-0002-9493-7325)
- Li‐Nien Chien (ORCID: https://orcid.org/0000-0001-9441-552X)
- Yi Lin (ORCID: https://orcid.org/0000-0002-3599-7758)
- Shing‐Jong Lin
Institutions
- University of Liverpool (GB)
- National Yang Ming Chiao Tung University (TW)
- National Central University (TW)
- Taipei Medical University Hospital (TW)
- Liverpool Heart and Chest Hospital (GB)
- Taipei Medical University (TW)
- Liverpool John Moores University (GB)
- Aalborg University (DK)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1002/bcp.70068
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Taipei Medical University
- Taipei Medical University Hospital